NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...

NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a ...

Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale ...

Graham G. Walmsley, a director at Akero Therapeutics, Inc. (NASDAQ:AKRO), recently acquired a significant amount of the company's common stock. According to a recent SEC filing, Walmsley purchased 200 ...

Akero Therapeutics (NASDAQ:AKRO – Free Report) had its price target boosted by UBS Group from $42.00 to $109.00 in a report issued on Friday,Benzinga reports.UBS Group currently has a buy rating ...

In this article, we are going to take a look at where Akero Therapeutics Inc (NASDAQ:AKRO) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 ...

In this article, we are going to take a look at where Akero Therapeutics Inc (NASDAQ:AKRO) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 after ...

In this article, we are going to take a look at where Akero Therapeutics Inc. (NASDAQ:AKRO) stands against the other stocks. Anyone who’s looked at the market in the last couple of weeks will ...